Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma By Ogkologos - May 14, 2026 173 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the RMC-6236-001 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Managing Side Effects with South Asian Foods July 19, 2022 Ralph, Medical Dog, Retires From Colorado Children’s Hospital To Focus On... July 29, 2021 Advanced and Metastatic Prostate Cancer Living Guideline June 11, 2026 New Research in Treating Non-Small Cell Lung Cancer: 2022 North America... December 1, 2022 Load more HOT NEWS Researchers Develop a Potential “Universal” CAR T-Cell Therapy for Blood Cancers Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α Adding Relacorilant to Nab-paclitaxel Prolongs OS in Patients with Platinum-Resistant Ovarian... Popular Fitness Blogger Maria Kang Removed Her Breast Implants Due To...
